Pulmatrix, Inc. (PULM) News
Filter PULM News Items
PULM News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest PULM News From Around the Web
Below are the latest news stories about PULMATRIX INC that investors may wish to consider to help them evaluate PULM as an investment opportunity.
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate UpdatePulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2023 and provided a corporate update on its development programs. |
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute MigrainePulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced the U.S. Food and Drug Administration ("FDA") has accepted the PUR3100 investigational new drug ("IND") application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Eval |
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled ItraconazolePulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology. PUR1900 is an orally inhaled dry powder formulation of the antifungal itraconazole, utilizing iSPERSE technology, being developed for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with asthma. |
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatePulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2023 and provided a corporate update on its development programs. |
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute MigrainePulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease, today announced the submission of an investigational new drug ("IND") application to the United States Food and Drug Administration ("FDA") for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE"), under development to treat acute migraine. The PUR3100 formulatio |
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache SocietyPulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced it will present data at the American Headache Society 65th Annual Meeting, being held from June 15th through 18th both virtually and in-person at the J.W. Marriott in Austin, Texas. |
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International ConventionPulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced that management will present at the annual Biotechnology Innovation Organization (BIO) International Convention, to be held in-person in Boston, MA, June 5 - 8, 2023. Presentation details are below. Pulmatrix management will also be available for one-on-one meeting |
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate UpdatePulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced first quarter financial results for 2023 and provided a corporate update on its development programs. |
Pulmatrix Supports World Asthma Day 2023Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced its support for World Asthma Day. |
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate UpdatePulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs. |